Angle PLC Announces Board Changes

Rhea-AI Summary

ANGLE plc, a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, has announced significant changes to its Board of Directors. Non-Executive Director Brian Howlett will retire at the upcoming AGM after 12 years of service, while Non-Executive Director Juliet Thompson has resigned effective immediately. The company is currently evaluating its Board structure and composition moving forward. Chairman Jan Groen expressed gratitude to both directors for their contributions, with Brian serving for twelve years and Juliet for two and a half years. ANGLE specializes in innovative CTC solutions used in research, drug development, and clinical oncology applications.

Positive

• Board restructuring opportunity allows for fresh perspectives and potential strategic alignment
• Orderly transition with planned retirement announcement provides time for succession planning

Negative

• Simultaneous departure of two experienced Non-Executive Directors could create temporary governance gap
• Immediate resignation of Juliet Thompson may indicate potential internal challenges

GUILDFORD, UNITED KINGDOM / ACCESS Newswire / June 6, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that Non-Executive Director, Brian Howlett, has informed the Board that after 12 years of service he will be retiring at the Company's upcoming AGM. Separately, Non-Executive Director, Juliet Thompson has informed the Board of her resignation with immediate effect.

The Company is reviewing the structure and composition for the Board moving forward.

ANGLE Chairman, Jan Groen, commented:

"On behalf of the Board and the Company, we thank Brian for his advice and support over the last twelve years and offer our best wishes on his retirement. We also thank Juliet for her contributions to ANGLE over the last two and a half years and wish her well with her future endeavours."

For further information:

ANGLE plc	+44 (0) 1483 343434
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser	+44 (0) 20 3207 7800
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix^® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.

Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

Any reference to regulatory authorizations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:

The Parsortix^® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K₂EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on ACCESS Newswire

FAQ

Why are two directors leaving ANGLE plc (ANPCY)?

Brian Howlett is retiring after 12 years of service, while Juliet Thompson has resigned with immediate effect. The company is reviewing its Board structure moving forward.

How long did Brian Howlett serve on ANGLE plc's Board?

Brian Howlett served as Non-Executive Director at ANGLE plc for 12 years before announcing his retirement.

What is ANGLE plc's main business focus?

ANGLE plc is a world-leading liquid biopsy company that develops innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology.

Who will replace the departing directors at ANGLE plc?

The company has not announced replacements yet but stated it is reviewing the structure and composition of the Board moving forward.

What is Juliet Thompson's tenure at ANGLE plc?

Juliet Thompson served as Non-Executive Director at ANGLE plc for two and a half years before her immediate resignation.